Oncotarget

Research Papers:

Differences in risk factors of malignancy between men and women with type 2 diabetes: A retrospective case-control study

Mariusz Dąbrowski _, Elektra Szymańska-Garbacz, Zofia Miszczyszyn, Tadeusz Dereziński and Leszek Czupryniak

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:66940-66950. https://doi.org/10.18632/oncotarget.17716

Metrics: PDF 734 views  |   HTML 1140 views  |   ?  


Abstract

Mariusz Dąbrowski1, Elektra Szymańska-Garbacz2, Zofia Miszczyszyn3, Tadeusz Dereziński4 and Leszek Czupryniak5

1University of Rzeszow, Faculty of Medicine, Institute of Nursing and Health Sciences, Rzeszów, Poland

2Medical University of Łódź, Department of Infectious and Liver Diseases, Łódź, Poland

3Private Clinic of Internal Diseases and Diabetes, Przemyśl, Poland

4NZOZ Esculap, Gniewkowo, Poland

5Warsaw Medical University, Department of Internal Diseases and Diabetology, Warsaw, Poland

Correspondence to:

Mariusz Dąbrowski, email: mariusz.dabrowski58@gmail.com, madab@esculap.pl

Keywords: cancer, diabetes, gender, insulin, metformin

Received: February 07, 2017     Accepted: April 27, 2017     Published: May 09, 2017

ABSTRACT

Background: The aim of this multicenter, retrospective, case-control study was to identify differences in risk factors of malignancy between men and women with type 2 diabetes.

Results: Among women the most prevalent malignancies were: breast and uterine cancers (35.6% and 14.4% respectively), while among men there were: colorectal and prostate cancers (24.5% and 13.3% respectively). In both gender metformin use was associated with lower cancer risk. Obesity and insulin treatment in dose-dependent and time-varying manner were associated with significantly increased risk of malignancy in females. In men, unexpectedly, cardiovascular disease was more prevalent in control group. Other variables did not show significant association with malignancy risk.

Materials and Methods: 118 women and 98 men with type 2 diabetes mellitus who developed cancer after diagnosis of diabetes and the same number of strictly age matched controls with type 2 diabetes and without malignancy were included into the study. Diabetes duration, antidiabetic medications use, glycated hemoglobin level, body mass index, smoking habits, occupation, presence of comorbidities and aspirin use were included into analyses.

Conclusions: Metformin demonstrated protective effect against cancer in both sexes. Obesity and insulin treatment seem to have greater impact on cancer risk among women.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17716